

Sarah E Cole

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7171372/publications.pdf>

Version: 2024-02-01

19
papers

358
citations

1477746

6
h-index

1125271

13
g-index

20
all docs

20
docs citations

20
times ranked

680
citing authors

#	ARTICLE	IF	CITATIONS
1	Cumulative menstrual months and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities Study. <i>International Journal of Cancer</i> , 2022, 150, 208-220.	2.3	0
2	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 351-360.e3.	0.9	14
3	A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2018, 36, e16136-e16136.	0.8	1
4	Monitoring Twitter Conversations for Targeted Recruitment in Cancer Trials in Los Angeles County: Protocol for a Mixed-Methods Pilot Study. <i>JMIR Research Protocols</i> , 2018, 7, e177.	0.5	10
5	A first-in-human phase I study of sEphB4-HSA (sEphB4) with expansion in hepatocellular (HCC) and cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2018, 36, 285-285.	0.8	1
6	A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D). <i>European Journal of Cancer</i> , 2016, 69, S11.	1.3	11
7	A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2501-2501.	0.8	75
8	A phase II study of capecitabine-oxaliplatin and cetuximab in patients (pts) with advanced/metastatic gastric cancer (G) or gastroesophageal junction (GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4096-4096.	0.8	0
9	Phase I clinical trial of temsirolimus (T) and vinorelbine (V) in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13084-e13084.	0.8	0
10	A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4124-4124.	0.8	2
11	Association of single-nucleotide polymorphisms (SNPs) in sodium channel, voltage-gated, type I, alpha subunit (SCN1A) with toxicity in metastatic colorectal cancer (mCRC) patients (pts) in a phase I study of patupilone (EPO906) and celebrex (C).. <i>Journal of Clinical Oncology</i> , 2011, 29, e14039-e14039.	0.8	0
12	A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 979-988.	1.1	52
13	A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 2533-2533.	0.8	1
14	A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2010, 28, 3059-3059.	0.8	0
15	Phase II study of capecitabine and gemcitabine in patients with metastatic colorectal cancer (mCRC). <i>Journal of Clinical Oncology</i> , 2009, 27, e15077-e15077.	0.8	1
16	Phase I dose and schedule finding study of pegylated liposomal doxorubicin (D) and weekly docetaxel (T). <i>Journal of Clinical Oncology</i> , 2006, 24, 12012-12012.	0.8	1
17	Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2057-2057.	0.8	4
18	EFFECT OF ALMONDS VS COMPLEX CARBOHYDRATES ON FASTING GHRELIN AND LEPTIN LEVELS DURING WEIGHT REDUCTION. <i>Journal of the American Dietetic Association</i> , 2003, 103, 82.	1.3	0

#	ARTICLE	IF	CITATIONS
19	Almonds vs complex carbohydrates in a weight reduction program. International Journal of Obesity, 2003, 27, 1365-1372.	1.6	185